Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited EBT Margin for the year ending June 30, 2024

Regencell Bioscience Holdings Limited EBT Margin is NA for the year ending June 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years